...
首页> 外文期刊>Archives of Pharmacal Research >Preparation and in vitro evaluation of povidone-sodium cholate-phospholipid mixed micelles for the solubilization of poorly soluble drugs
【24h】

Preparation and in vitro evaluation of povidone-sodium cholate-phospholipid mixed micelles for the solubilization of poorly soluble drugs

机译:聚维酮-胆酸钠-磷脂混合胶束的制备及其体外增溶作用

获取原文
获取原文并翻译 | 示例
           

摘要

Mixed micelles made of polyvinylpyrrolidone (PVP), sodium cholate, and phospholipids were prepared to improve the solubility of poorly water-soluble drugs. Sylibin, a drug used in treating liver diseases, was incorporated into the mixed micelles. The formulation of sylibin containing PVP-sodium cholate-phospholipid mixed micelles with an optimized composition (PVP/sodium cholate/phospholipid/silybin = 3:3:4:1∼2 by weight) was obtained based on the study of pseudoternary phase diagrams. The critical micelle concentration was used to evaluate the micellar stability towards dilution. The results showed that addition of PVP to sodium-cholate-phospholipid mixed micelles increased stability. The solubility of sylibin in PVP-sodium cholate-phospholipid mixed micelles was higher than that in pure water or in sodium cholate-phospholipid mixed micelles. In a stability study, we found that PVP-sodium cholate-phospholipid mixed micelles showed good stability. After 3 months storage at 40°C, just 2.6% sylibin was lost with only minor changes of the particle size when compared to a reference formulation containing sodium cholate and phospholipid mixed micelles. In addition, the developed formulation significantly improved in vitro drug release. The time required to release 50% sylibin (t50%) from sodium cholate and phospholipid mixed micelles was 326 h, while the t50% from PVP-sodium cholate-phospholipid mixed micelles was only 51.1 h. Our results suggest that these mixed micelles might have significant potential application to the biomedical field.
机译:制备了由聚乙烯吡咯烷酮(PVP),胆酸钠和磷脂制成的混合胶束,以改善水溶性差的药物的溶解度。 Sylibin,一种用于治疗肝脏疾病的药物,被掺入了混合胶束中。基于伪三元相图的研究,获得了含有优化成分的PVP-胆酸钠-磷脂混合胶束(PVP /胆酸钠/磷脂/水飞蓟宾= 3:3:4:1〜2)的sylibin制剂。临界胶束浓度用于评估胶束对稀释的稳定性。结果表明,向胆酸钠-磷脂混合胶束中添加PVP可以提高稳定性。 sylibin在PVP-胆酸钠-磷脂混合胶束中的溶解度高于在纯水中或在胆酸钠-磷脂混合胶束中的溶解度。在稳定性研究中,我们发现PVP-胆酸钠-磷脂混合胶束显示出良好的稳定性。与包含胆酸钠和磷脂混合胶束的参考制剂相比,在40°C下储存3个月后,仅失去了2.6%的sylibin,粒径仅有微小变化。另外,开发的制剂显着改善了体外药物释放。从胆酸钠和磷脂混合胶束中释放50%sylibin(t50%)所需的时间为326小时,而从PVP-胆酸钠-磷脂混合胶束中释放50%的时间仅为51.1 h。我们的结果表明,这些混合胶束可能在生物医学领域具有重要的潜在应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号